Multiple sclerosis is an immune-mediated inflammatory and demyelinating disease in the central nervous system (CNS) which produce axonal loss, impairment of oligodendrocytes and neurons. Although by our knowledge is multiple sclerosis untreateble, we can treated it on third levels: to reduce activity disease, (disease modify therapy, DMT), enhancing remyelination (protein growth factors) and a third therapeutic approach improving conduction of demyelinated fibers, is represented by the potassium chanel blockers, 4-aminopyridine (4 AP. Fampridine). The objective of this article is our first oppinion with fampridine in group of 41 patients with secundary progressive Multiple sclerosis.
Key Words: Fampridine, multiple sclerosis, 4-AP, CNS